Positively UK welcomes the findings from PROUD and IPERGAY studies, which demonstrate the high effectiveness of usingPre-Exposure Prophylaxis (PrEP) as an effective tool for HIV prevention and promoting the health of gay men and men who have sex with men. Positively UK joins other UK based HIV and LGBT organisations in urging the NHS to speed up the approval process and make PrEP available.
18 hours ago | Positively UK
Take a pill daily and prevent the contraction of HIV 99 percent of the time. That is the narrative presented to many young men who have sex with men (MSM) by their peers regarding pre-exposure prophylaxis (PrEP). And, as is normally the case with anything framed in such a simple manner, the nuances of treatment fall through the cracks. It is unwise to herald PrEP as the key to freeing a generation from HIV. It is merely one piece of a larger effort. Not only is PrEP not for everyone, but public health activists face political obstacles similar to those hurled at advocates of birth control.
01 April 2015 | Yale Daily News
As a clinician who has witnessed the devastating impact of the HIV/AIDS epidemic since the 1980s, Sheena McCormack is enthusiastic about her latest project, the UK Medical Research Council (MRC) PROUD study. As lead investigator, she has been investigating the effect of pre-exposure prophylaxis (PrEP) to protect against HIV infection in high-risk men who have sex with men (MSM). PROUD has shown that PrEP reduces new HIV infections by 86%.
28 March 2015 | The Lancet
This survey yields some disturbing findings. Overall, the HIV science and treatment knowledge of the HIV/AIDS workforce is far too low. In many cases, people working in HIV/AIDS appear to doubt the science behind breakthrough biomedical tools for HIV prevention, and far too many members of the workforce are not familiar with many of the bio-medical interventions that will play a critical role in ending the epidemic.
18 March 2015 | Black AIDS Institute
On average, the survey respondents answered just 63 percent of the questions correctly, including 76 percent of those covering basic knowledge and terminology, 56 percent of the HIV treatment questions, and 46 percent of those on the use of ARVs to prevent transmission of the virus. Only 19 percent of the respondents scored 80 percent or higher on the test.
18 March 2015 | AIDSMeds
Our best guess is that generic Truvada could be available in December 2017, initially produced by Teva, a major generic producer. Two other generic companies, Lupin Pharmaceuticals and Cipla may follow soon after creating competition that can really bring prices down.
17 March 2015 | Ethan The Blog
Much-anticipated efficacy results from a French study of intermittent PrEP were announced at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) at the end of February. Although PrEP experts do not have enough information from this relatively small study of men to advise or recommend intermittent PrEP use, Ipergay does add to clinical knowledge about one important issue: how to stop using PrEP if it’s no longer needed.
13 March 2015 | BETA
Patients seeking drugs to prevent HIV infection may face resistance from primary care doctors who are not trained in HIV care. Some frustrated patients have launched personal educational campaigns to get the word out.
10 March 2015 | Healthline
PATH, in collaboration with the US National Institutes of Health (NIH) and the HIV Prevention Trials Network (HPTN), has launched a new study to test the safety and acceptability of a long-acting injectable formulation of the proven antiretroviral drug rilpivirine (TMC278) as a pre-exposure prophylaxis (PrEP) against HIV.
06 March 2015 | PATH
US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.
03 March 2015 | Star Observer